Protein A Resin Market - Growth, Trends, and Forecasts (2023 - 2028)

The protein A resin market is expected to register a CAGR of around 8.5% over the forecast period.

The emergence of the COVID-19 disease had a notable impact on the growth of the market over the pandemic period. This sudden outbreak led to unprecedented demand for effective diagnostics and highly safe manufacturing of COVID-19 therapeutics. Such circumstances have lured the market players to adopt protein A resin in the manufacture of COVID-19 vaccines, thereby impacting the market growth. For instance, in February 2021, Prepligen collaborated with Navigo Proteins and developed a unique purification resin, NGL COVID-19 Spike Protein Affinity Resin. The resin is used to purify COVID-19 vaccines and is used in binding to the SARS-CoV-2 spike protein binding to the receptor binding domain. Thus, these developments have had a crucial impact on the growth of the market over the pandemic period. In addition, the demand for protein A resin is expected to remain intact due to the emergence of mutant strains of the SARS-CoV-2 virus, thereby contributing to the growth of the market over the forecast period.

The growth of the protein A resin market is majorly attributed to the increasing burden of chronic diseases across the globe and the rising demand for therapeutics for antibodies in order to treat chronic disorders. Additionally, the efficacy of protein A-resin in the diagnosis of various chronic diseases is also expected to boost the growth of the market. For instance, an NCBI article published in May 2021, mentioned that a low-cost thermophoretic aptasensor (TAS) is used to profile cancer-associated protein profiles of plasma EVs without the interference of soluble proteins. This demonstrated that protein analysis has a high accuracy of 91.1% for discrimination of metastatic breast cancer, non-metastatic breast cancer, and healthy donors (HD). Thus, studies proving the efficiency of protein A resin in cancer diagnosis are expected to contribute to the growth of the market.

Additionally, the rising burden of chronic diseases is also expected to contribute to the growth of the market. For instance, as per a WHO factsheet published in February 2022, in 2021, there were an estimated 1.9 million new cancer cases diagnosed in the United States. The report also mentioned that each year, approximately 400,000 children develop cancer globally. Cervical cancer is the most common in 23 countries such as Eswatini, India, South Africa, Latin America, and others. The most common cancers are breast, lung, colon and rectum, and prostate cancers.

While several factors contribute to the growth of the market, the high cost associated with protein A-resin is expected to impede the growth of the market over the forecast period.

Protein A Resin Market Trends

Pharmaceutical and Biopharmaceutical Companies are Expected to Dominate the End User Segment

Pharmaceutical and biopharmaceutical companies mainly use proteins as the principal target, and thus, protein analysis has a very important role in drug discovery and development in the pharma and biotech industries. The common application of protein analysis involves target identification, evaluation, identification of efficacy and toxicity biomarkers from readily accessible biological fluids, and investigations into mechanisms of drug action or toxicity, among others, which in turn is expected to grow significantly due to a large number of ongoing drug development projects in the pharmaceutical and biopharmaceutical projects across the world.

A rise in government funding for pharmaceutical research and development and technological advancements in the area of analytical instruments are expected to drive the growth of the studied segment. Also, increasing life science R&D expenditure, progressing drug discovery, and an increase in the adoption of chromatography are key factors driving the growth of the protein A resins market in the pharmaceutical and biopharmaceutical industries. For instance, the data published by EFPIA in 2022 mentioned that the research and development expenditure of the pharmaceutical industry in Europe in 2021 was EUR 41.5 million (USD 44.6 million). Such high pharmaceutical expenditures are expected to drive the demand for protein A resin in drug development research and the development of various diagnostic tests, thereby boosting the growth of the studied segment.

Additionally, increasing product launches in order to address the demand from the pharmaceutical and biopharmaceutical industries are also expected to contribute to the growth of the market. For instance, in September 2021, Purolite launched two novel next-generation chromatography resins, Praesto Jetted A50 HipH, and Praesto Jetted dt 18-DVD to address the diversity of biomolecule pipelines of antibodies, vaccines, and gene therapy.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

The market for protein A resin in the North American region is expected to experience lucrative growth owing to the factors such as the rising burden of infectious and chronic diseases, technological advancements in the studied market, and increasing research and development expenditure on pharmaceutical and biological research. In addition, the product launches and strategic initiatives by key market players will also contribute to the market growth.

For instance, according to the American Cancer Society Inc., data published in 2022, in 2021, there were an estimated 1.9 million new cancer cases diagnosed in the United States. In addition, according to the Public Health Agency of Canada data published in October 2021, approximately 2 in 5 Canadians were diagnosed with cancer in their lifetime, and in 2021, an estimated 229,000 Canadians were diagnosed with cancer. The report also mentioned that lung, breast, colorectal, and prostate cancers were expected to remain the most commonly diagnosed cancers, accounting for nearly 46% of all cancer diagnoses in 2021. Such a high prevalence of chronic diseases in North American countries is expected to contribute to the demand for protein A resin for diagnostic purposes and the development of appropriate therapies, thereby boosting the market growth.

On the other hand, the rising product launches by various market players to meet the growing demand for protein A resin is also expected to fuel the market growth in this region. For instance, in March 2022, Sengenics launched an autoantibody profiling service - the ‘Pan-Autoimmune Protein Array 1.0’ for efficient identification and quantitation of autoantibody disease biomarker signatures. It is a protein microarray-based, multiplexed immunoassay which utilizes Sengenics’ KREX protein folding technology and optimized computational analysis.

Protein A Resin Industry Overview

The protein A resin market is moderately competitive, with a presence of mostly global companies. Companies are taking the initiative to grow their presence in the Protein A Resin market. Key players expected to dominate the Protein A Resin market are Thermofisher Scientific Inc., GE Healthcare, Merck KGaA, Agarose Beads Technologies, Bio-Rad Laboratories, Inc., Expedeon Ltd., Genscript Corporation, Novasep, Purolite Lifescience, and Repligen.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.